PH12022551013A1 - Pyridazinones as parp7 inhibitors - Google Patents

Pyridazinones as parp7 inhibitors

Info

Publication number
PH12022551013A1
PH12022551013A1 PH1/2022/551013A PH12022551013A PH12022551013A1 PH 12022551013 A1 PH12022551013 A1 PH 12022551013A1 PH 12022551013 A PH12022551013 A PH 12022551013A PH 12022551013 A1 PH12022551013 A1 PH 12022551013A1
Authority
PH
Philippines
Prior art keywords
pyridazinones
parp7
inhibitors
parp7 inhibitors
cancer
Prior art date
Application number
PH1/2022/551013A
Other languages
English (en)
Inventor
Kevin Wayne Kuntz
Nicholas Robert Perl
Melissa Marie Vasbinder
Original Assignee
Ribon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribon Therapeutics Inc filed Critical Ribon Therapeutics Inc
Publication of PH12022551013A1 publication Critical patent/PH12022551013A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PH1/2022/551013A 2019-10-30 2020-10-29 Pyridazinones as parp7 inhibitors PH12022551013A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962927934P 2019-10-30 2019-10-30
PCT/US2020/057831 WO2021087025A1 (en) 2019-10-30 2020-10-29 Pyridazinones as parp7 inhibitors

Publications (1)

Publication Number Publication Date
PH12022551013A1 true PH12022551013A1 (en) 2023-03-06

Family

ID=73699388

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2022/551013A PH12022551013A1 (en) 2019-10-30 2020-10-29 Pyridazinones as parp7 inhibitors

Country Status (13)

Country Link
US (2) US11691969B2 (cg-RX-API-DMAC7.html)
EP (1) EP4051384A1 (cg-RX-API-DMAC7.html)
JP (1) JP7641957B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220109401A (cg-RX-API-DMAC7.html)
CN (1) CN114761086B (cg-RX-API-DMAC7.html)
AR (1) AR120338A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020375821B2 (cg-RX-API-DMAC7.html)
CA (1) CA3159188A1 (cg-RX-API-DMAC7.html)
IL (1) IL292432B1 (cg-RX-API-DMAC7.html)
MX (1) MX2022005216A (cg-RX-API-DMAC7.html)
PH (1) PH12022551013A1 (cg-RX-API-DMAC7.html)
TW (1) TWI902715B (cg-RX-API-DMAC7.html)
WO (1) WO2021087025A1 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020022006A2 (pt) 2018-04-30 2021-01-26 Ribon Therapeutics Inc. piridazinonas como inibidores de parp7
US11293927B2 (en) 2018-04-30 2022-04-05 Ribon Therapeutics, Inc. Screening methods for PARP modulators
WO2020223229A1 (en) 2019-04-29 2020-11-05 Ribon Therapeutics, Inc. Solid forms of a parp7 inhibitor
TWI902715B (zh) 2019-10-30 2025-11-01 美商律幫治療股份有限公司 作為parp7抑制劑的嗒酮
CN116157396B (zh) * 2020-11-27 2025-07-18 康百达(四川)生物医药科技有限公司 哒嗪酮衍生物及其在医药上的应用
US20240166664A1 (en) * 2021-02-03 2024-05-23 Shanghai Apeiron Therapeutics Company Limited Triheterocyclic compound, preparation method therefor, and application thereof
EP4291560A4 (en) * 2021-02-09 2025-01-15 Jacobio Pharmaceuticals Co., Ltd. TRICYCLIC DERIVATIVES USEFUL AS PARP7 INHIBITORS
WO2022188889A1 (zh) * 2021-03-12 2022-09-15 杭州英创医药科技有限公司 作为parp7抑制剂的化合物
CN117279917A (zh) * 2021-05-21 2023-12-22 成都百裕制药股份有限公司 哌嗪衍生物及其在医药上的应用
WO2022247839A1 (zh) * 2021-05-25 2022-12-01 山东轩竹医药科技有限公司 Parp7抑制剂
CN115477640A (zh) * 2021-05-31 2022-12-16 由理生物医药(上海)有限公司 作为parp7抑制剂的哒嗪酮类化合物
WO2023001247A1 (zh) * 2021-07-21 2023-01-26 南京明德新药研发有限公司 哒嗪酮类化合物
WO2023001296A1 (zh) * 2021-07-23 2023-01-26 武汉人福创新药物研发中心有限公司 作为parp7抑制剂的哒嗪酮类化合物
WO2023011629A1 (zh) * 2021-08-06 2023-02-09 成都百裕制药股份有限公司 吡咯烷酮衍生物及其在医药上的应用
WO2023020479A1 (zh) * 2021-08-16 2023-02-23 重庆华森制药股份有限公司 Parp7抑制剂及其应用
EP4423078A1 (en) 2021-10-28 2024-09-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
CN115745971B (zh) * 2021-12-20 2024-07-30 北京华森英诺生物科技有限公司 Parp7抑制剂及其应用
CN116444497B (zh) * 2022-01-14 2025-06-24 如东凌达生物医药科技有限公司 一类哒嗪酮类化合物、制备及其应用
CA3248911A1 (en) 2022-01-28 2023-08-03 Gilead Sciences, Inc. POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS
WO2023185073A1 (zh) * 2022-04-01 2023-10-05 诺沃斯达药业(上海)有限公司 Parp7抑制剂及其用途
CN117586263B (zh) * 2022-08-09 2026-04-10 康百达(四川)生物医药科技有限公司 哌嗪衍生物及其在医药上的应用
EP4570249A4 (en) * 2022-08-09 2026-07-22 Kangbaida Sichuan Biotechnology Co Ltd USE OF A PIPERAZINE COMPOUND IN COMBINATION WITH RADIOTHERAPY FOR THE TREATMENT OF A TUMOR
TW202416984A (zh) * 2022-08-17 2024-05-01 大陸商北京加科思新藥研發有限公司 化合物i或其鹽的固體形式
CN117164524B (zh) * 2022-09-06 2026-02-03 杭州师范大学 具有parp7/hdac双靶点抑制活性的哒嗪酮衍生物及其制备方法和应用
WO2024149231A1 (en) * 2023-01-10 2024-07-18 Angel Pharmaceutical Co., Ltd. Parp7 inhibitors and uses thereof
CN118388414A (zh) * 2023-01-17 2024-07-26 中国药科大学 哒嗪酮类化合物及其制备方法、药物组合物和应用
CN121752568A (zh) * 2023-08-29 2026-03-27 康百达(四川)生物医药科技有限公司 一种哌嗪衍生物的制备工艺及其中间体

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3255293B2 (ja) 1997-09-05 2002-02-12 松下電器産業株式会社 蛍光偏光法
WO2002082082A2 (en) 2001-04-09 2002-10-17 Boehringer Ingelheim Pharmaceuticals, Inc. Fluorescence polarization assay
HU227237B1 (en) 2001-09-27 2010-12-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Substituted alkylpyridazinone derivatives, process for their preparation, pharmaceutical compositions containing them
GB0301628D0 (en) 2002-09-19 2003-02-26 Aventis Pharma Inc Method for assaying compounds that decrease the activity of poly (ADP-ribose) - polymerase (PARP)
CA2568835C (en) 2004-06-30 2014-05-27 Janssen Pharmaceutica N.V. Quinazolinone derivatives as parp inhibitors
GB0610680D0 (en) 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
EP2502918B1 (en) 2006-07-25 2015-03-25 Cephalon, Inc. Pyridazinone Derivatives
MX347085B (es) 2006-12-28 2017-04-06 Abbott Laboratories * Inhibidores de la poli (adp-ribosa) polimerasa.
JP5758630B2 (ja) * 2007-11-15 2015-08-05 エンメエッセディ・イタリア・エッセ・エッレ・エッレ Parp阻害剤としてのピリダジノン誘導体
DK2271626T3 (en) 2008-03-27 2015-02-23 Janssen Pharmaceutica Nv TETRAHYDROPHENANTHRIDINONES AND TETRAHYDROCYCLOPENTAQUINOLINONES AS INHIBITORS OF POLYMERIZATION OF PARP AND TUBULIN
NZ623069A (en) 2009-08-17 2015-11-27 Sloan Kettering Inst Cancer Heat shock protein binding compounds, compositions, and methods for making and using same
RU2013150102A (ru) 2011-04-11 2015-05-20 Эббви Инк. Ингибиторы parp для лечения cipn
US20150182490A1 (en) 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
CN103570725B (zh) 2012-08-01 2017-03-22 中国科学院上海药物研究所 哌嗪并三唑类化合物及其制备方法和用途
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
EP2970289A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
WO2016116602A1 (en) 2015-01-23 2016-07-28 Astrazeneca Ab Treatment of cancer
CN106749261A (zh) 2015-11-23 2017-05-31 中国科学院上海药物研究所 一类取代三唑并哌嗪类parp抑制剂及其制备方法和用途
TWI785022B (zh) 2017-03-28 2022-12-01 美商富曼西公司 新穎噠嗪酮類除草劑
US12435078B2 (en) 2017-09-18 2025-10-07 Gfb (Abc), Llc Pyridazinones and methods of use thereof
GB201717080D0 (en) 2017-10-18 2017-11-29 Syngenta Participations Ag Chemical process
BR112020022006A2 (pt) 2018-04-30 2021-01-26 Ribon Therapeutics Inc. piridazinonas como inibidores de parp7
US11293927B2 (en) 2018-04-30 2022-04-05 Ribon Therapeutics, Inc. Screening methods for PARP modulators
WO2020223229A1 (en) 2019-04-29 2020-11-05 Ribon Therapeutics, Inc. Solid forms of a parp7 inhibitor
WO2021087018A1 (en) 2019-10-30 2021-05-06 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors
TWI902715B (zh) 2019-10-30 2025-11-01 美商律幫治療股份有限公司 作為parp7抑制劑的嗒酮
JP7382261B2 (ja) 2020-03-19 2023-11-16 株式会社日立製作所 情報処理装置及び方法

Also Published As

Publication number Publication date
CN114761086B (zh) 2025-07-22
EP4051384A1 (en) 2022-09-07
CN114761086A (zh) 2022-07-15
US12617782B2 (en) 2026-05-05
TWI902715B (zh) 2025-11-01
TW202128653A (zh) 2021-08-01
JP7641957B2 (ja) 2025-03-07
WO2021087025A1 (en) 2021-05-06
KR20220109401A (ko) 2022-08-04
US11691969B2 (en) 2023-07-04
MX2022005216A (es) 2022-06-02
CA3159188A1 (en) 2021-05-06
US20240034728A1 (en) 2024-02-01
IL292432A (en) 2022-06-01
JP2023501253A (ja) 2023-01-18
IL292432B1 (en) 2026-05-01
AR120338A1 (es) 2022-02-09
AU2020375821A1 (en) 2022-06-02
AU2020375821B2 (en) 2026-03-19
US20210130342A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
PH12020551760A1 (en) Pyridazinones as parp7 inhibitors
MX2025003445A (es) Amidas heterobiciclicas como inhibidoras del cumulo de diferenciacion 38 (cd38)
MX2022005216A (es) Piridazinonas como inhibidores de poli(adp-ribosa) polimerasa 7 (parp7).
PH12022550892A1 (en) Bicyclic heterocycles as fgfr inhibitors
MY196836A (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).
EP4674415A3 (en) Azaquinolines as inhibitors of cd38
PH12020500072A1 (en) Heterocyclic inhibitors of atr kinase
MX2018005600A (es) Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello.
MX2017012738A (es) Inhibidores de indolamina 2.3-dioxigenasa (ido) para el tratamiento de cancer.
PH12015502028A1 (en) Ido inhibitors
MX2015011374A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
MX2016002075A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
MX366875B (es) Inhibidores de indoleamina 2,3-dioxigenasa (ido).
MX2015017486A (es) Inhibidores de indolamina 2,3-dioxigenasa (dio).
PH12019502049A1 (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
EA201790502A1 (ru) Ингибиторы гистоновых диметилаз
PH12021552588A1 (en) Cd73 inhibitors
WO2019023315A3 (en) Rac inhibitors
MX2017015923A (es) Inhibidores de indolamina-2,3-dioxigenasa (ido).
MX2020012782A (es) Inhibidor de ccr5 para el uso en el tratamiento de cancer.
MX2021009863A (es) Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
AU2020378127A8 (en) Compounds as CD73 inhibitors
MX2020012805A (es) Compuestos para el tratamiento del dolor, composiciones que comprenden los mismos, y metodos para utilizar los mismos.
MX381727B (es) Inhibidores heterociclicos de la proteina cinasa 1 dependiente de 3-fosfoinositido (pdk1) para usarse en el tratamiento del cancer.